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RESEARCH ARTICLE
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Abstract
Introduction: The clinical translation of biofluid markers for dementia requires validation in diverse cohorts. The study goal was to evaluate if blood biomarkers reflecting
diverse pathophysiological processes predict disease progression in Mexican American adults. Methods: Mexican American adults (n = 745), 50 years of age and older,
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completed annual assessments over a mean of 4 years. Serum collected at baseline was
assayed for total tau, neurofilament light (NFL), ubiquitin carboxyl-terminal hydrolase
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LI, glial fibrillary acidic protein (GFAP), soluble cluster of differentiation 14 (sCD14),
and chitinase-3-like protein 1 (YKL-40). Results: Higher GFAP and NFL were associated with global cognitive decline. Only GFAP was associated with increased incident
dementia risk (hazard ratio: 1.611 (95% confidence interval: 1.204-2.155)) and inclusion of additional biomarkers did not improve model fit. Discussion: Among a panel
of six blood biomarkers previously associated with neurodegenerative disease, only
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GFAP predicted incident dementia in our cohort. The findings suggest that blood GFAP
levels may aid dementia-risk prediction among Mexican American adults.
KEYWORDS

Alzheimer’s disease, biomarkers, GFAP, Hispanic, Latinos, Mexican American, NFL, soluble CD14,
total tau, UCHL-1, YKL-40

1

INTRODUCTION

of health may affect ADRD biomarker levels. Given the observed variances in biomarker performance across ethnoracial groups, the valida-

Alzheimer’s disease (AD), a progressive neurodegenerative condition

tion of ADRD biomarkers in diverse cohorts has been highlighted as a

that gradually causes cognitive and functional decline, is a top contrib-

critical priority for the field.7

utor to mortality in the United

States.1

AD is a clinically and biologi-

The goal of the present study was to evaluate the ability of ADRD

cally heterogeneous disorder that develops insidiously over the span

blood biomarkers to predict cognitive decline, clinical conversion, and

of decades.2 Cerebral amyloid beta (Aβ) deposition, followed by neu-

disease progression in a cohort of Mexican American older adults

rodegeneration and phosphorylated tau accumulation, are hallmarks

followed over a mean of 4 years. Given the heterogeneity of ADRD,2

disease.3

In addition, growing research supports the central

we investigated a panel of blood markers reflecting diverse pathophys-

role of broader pathophysiological processes including neuroinflam-

iological processes including neuronal/axonal injury (t-tau, NFL), ubiq-

mation, glial dysfunction, synaptic loss, hypoperfusion, and metabolic

uitin protease system clearance (ubiquitin carboxyl-terminal hydrolase

alterations.2,4,5 The complexity of the disease poses challenges to accu-

L1 [UCHL1]), and glial injury (soluble cluster of differentiation 14

rate diagnosis and therapeutic discovery. Biofluid markers, particularly

(sCD14), YKL-40, GFAP). Based on prior research,14 we hypothesized

in blood, hold the potential to aid early diagnosis, improve monitoring

that markers of neuronal/axonal and glial injury would predict cogni-

of disease progression, and foster individualized precision-medicine

tive decline and clinical conversion in our cohort. As an exploratory aim,

approaches to treatment.4 Over the past decade, tremendous progress

we further evaluated if the associations between biomarker levels and

has been made in the validation of blood markers with diagnostic accu-

clinical outcomes were influenced by the presence of the apolipopro-

racy for AD and related dementias (ADRD), including neurofilament

tein E (APOE) ε4 allele. Among non-Hispanic Whites, the APOE ε4 allele

light (NFL), total tau (t-tau), and more recently, phosphorylated tau (p-

is the strongest known genetic risk factor for sporadic AD.15 However,

tau) 181 and 217.6

in Mexican Americans, the APOE ε4 allele has been found to display

of the

Despite the substantial achievements in the field, advancements

weaker and more inconsistent associations with cognitive impair-

have not extended to all groups equitably. Ethnoracial minorities in the

ment and dementia endophenotypes.16,17 The impact of the APOE ε4

United States have elevated risk of ADRD,1 yet the majority of blood

allele on ADRD blood biomarker levels remains unestablished among

biomarker research has focused primarily on non-Hispanic White pop-

Mexican Americans.

ulations. Emerging research suggests that ADRD biomarker levels may
differ across ethnoracial groups, which may propagate further disparities in diagnostic accuracy, advanced care planning, and research
engagement.7

2

METHODS

Several studies have reported lower t-tau and p-tau 181

levels in Black adults as compared to non-Hispanic White adults,8–11

2.1

Participants

which may affect the sensitivity of cut-off values used for diagnosis.11
Latinos of Mexican descent are the most populous ethnic group in

Stored serum biospecimens were obtained from participants complet-

the United States, yet remain highly understudied in ADRD biomarker

ing the baseline visit of the Texas Alzheimer’s Research and Care Con-

research.12 Prior proteomic research conducted by O’Bryant et al.

sortium (TARCC) study. As described previously,18 TARCC is a collabo-

reported significant differences in the plasma signature for ADRD

rative research effort to establish a consortium of Alzheimer’s Disease

betweenMexican Americans and non-Hispanic Whites, with a stronger

Centers across 10 academic institutions, which was initially funded by

Americans.12,13

Within a

the State of Texas in 1999. Annual assessment visits include a clini-

bi-ethnic cohort of Hispanics and non-Hispanic Whites, we previ-

cal examination, medical history, neuropsychological evaluation, and

ously reported that serum levels of NFL, glial fibrillary acidic protein

blood draw. Inclusion criteria for the TARCC study included age 50

(GFAP), and chitinase-3-like protein 1 (YKL-40) were associated with

years or older at the time of enrollment. For the current project, inclu-

poorer cognition, but the associations were typically weaker among

sion criteria additionally included Mexican American ethnicity, stored

Hispanics.14 It is notable that the ethnic differences were no longer

serum from the baseline visit, and completion of at least one annual

significant when examining a demographically matched sub-sample of

follow-up visit. The six serum biomarkers assessed were available on all

Hispanic and non-Hispanic White adults, highlighting the need to bet-

participants. The study was approved by the institutional review board

ter understand how disparities across multidimensional determinants

at each enrolling institution and was conducted in adherence with The

metabolic endophenotype among Mexican
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Code of Ethics of the World Medical Association. Participants provided
written informed consent prior to enrollment with appropriate legal

HIGHLIGHTS

representation for individuals lacking capacity to consent. Local insti-

∙ Higher baseline serum glial fibrillary acidic protein (GFAP)

tutional review board approval was obtained to process and analyze

and neurofilament light (NFL) were associated with global

de-identified samples and clinical/demographic data.

cognitive decline
∙ Higher baseline serum GFAP, NFL, chitinase-3-like pro-

2.2

tein 1 (YKL-40), and soluble cluster of differentiation 14

Neuropsychological evaluation

(sCD14) associated with disease progression
∙ Serum GFAP, unlike total tau, NFL, UCHL-1, YKL-40, and

The neuropsychological evaluation was administered in English or

sCD14, predicted incident dementia

Spanish in alignment with the participant’s preference. The battery
included measures of global cognition (Mini Mental Status Examination
[MMSE]),19 learning and memory (Weschler Memory Scale, Third Edition [WMS-3] Logical Memory (LM) I and II20 ]), attention/processing
speed (Trail Making Test Part A21 ), executive function (Trail Making

RESEARCH IN CONTEXT

Test Part B21 ), and language (Animal Fluency22 ).
The Clinical Dementia Rating Scale (CDR) was also completed with

1. Systematic Review: Emerging research suggests that

participants and their study partners.23

biomarkers for Alzheimer’s disease and related dementias may differ across ethnoracial groups, which may
serve to further propagate health disparities in diagno-

2.3

Consensus reviews

sis and treatment if left unexamined. Latinos of Mexican descent are the fastest growing demographic group

Clinical diagnoses were assigned at each site from a consensus review

in United States, yet they remain highly understudied in

panel that included at least one physician, neuropsychologist, and

biomarker research.

research coordinator. National Institute of Neurological and Commu-

2. Interpretation: Study findings suggest that serum levels

nicative Diseases and Stroke/Alzheimer’s Disease and Related Dis-

of neurofilament light (NFL), glial fibrillary acidic protein

orders Association (NINCDS-ADRDA) criteria were applied to assign

(GFAP), chitinase-3-like protein 1 (YKL-40), and soluble

diagnoses of possible or probable AD.24 Mild cognitive impairment

cluster of differentiation 14 (sCD14) were associated

(MCI) subtypes (amnestic vs non-amnestic) were defined using estab-

with worsening disease severity in Mexican American

lished criteria by Petersen et al.25

older adults. GFAP was the only biomarker significantly
associated with increased risk of incident dementia risk
and inclusion of additional biomarkers did not improve

2.4

Blood draw and storage

model fit.
3. Future Directions: Findings suggest that blood levels of

TARCC collected and processed blood from participants in accordance

GFAP may uniquely aid prediction of dementia risk among

with established guidelines for ADRD research.26 Briefly, venipuncture

Mexican Americans. Further validation studies in Mexi-

with a 21 gauge needle was used to collect non-fasting blood in the

can American adults and other diverse cohorts are nec-

morning. Serum tubes were allowed to clot for at least 30 minutes,

essary for clinical translation.

while plasma tubes were inverted 5 to 10 times. Within 1 hour of collection, tubes were centrifuged for 10 minutes at 2000 x g. Next, 500 uL
aliquots were transferred to polypropylene tubes and placed into −80◦
freezers within 2 hours of collection. APOE genotyping was performed

(ELISAs; R&D Systems, Minneapolis, MN). Analytical ranges and inter-

with polymerase chain reaction (PCR) as described previously.18 For

assay coefficients of variance have been reported previously.14 A certi-

the current project, samples were shipped to the Laboratory for Clin-

fied laboratory-technician, who was blinded to demographic and clini-

ical Biochemistry at the University of Vermont for biomarker assays.

cal data, performed all assays between November and December 2019
using a single batch of reagents.

2.5

Assays
2.6

Statistical analyses

The Simoa Neurology 4-Plex Kit Serum was used to quantify serum
levels of t-tau, NFL, UCHL1, and GFAP using a Simoa HD-1 Ana-

All biomarker values, with the exception of sCD14, were skewed and

lyzer (Quanterix, Lexington, MA). sCD14 and YKL-40 assays were

were natural log transformed to normalize their distributions. The

performed using commercial enzyme-linked immunosorbent assays

biomarker values were then standardized prior to analyses. To limit

4 of 10
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data loss, t-tau values below the detection limit were set equal to the

measures of learning and memory. Higher baseline levels of NFL, GFAP,

detection limit (0.09 pg/mL) prior to log transformation, since values

YKL-40, and sCD14 were associated with ADRD disease progression

were known to be at this level or below.14 Differences in demograph-

as evaluated by the CDR Sum of Boxes (Table 3).

ics and clinical characteristics across the diagnostic groups at baseline

Stratified analyses by APOE ε4 carrier status indicated associations

were assessed with the chi-square statistic for categorical variables or

between baseline NFL, GFAP, and YKL-40 levels with worsening global

with Kruskal-Wallis tests for continuous variables. The association of

cognition among ε4 carriers (Table S2). NFL and YKL-40 were asso-

each biomarker with cognitive decline was evaluated using separate

ciated with faster immediate recall decline and t-tau was associated

generalized estimating equation (GEE) analyses, where mean cogni-

with faster semantic fluency decline among ε4 carriers. Among APOE

tive change over time was modeled as a function of biomarker (stan-

ε4 non-carriers, only t-tau was associated with accelerated memory

dardized), time, time by biomarker, and covariates (age, sex, education,

decline. NFL, GFAP, and YKL-40 were associated with ADRD progres-

site, APOE ε4 status [at least one ε4 allele vs none], clinical diagnosis

sion among APOE ε4 carriers, whereas as no significant associations

at baseline, body mass index [BMI], diabetes, systolic blood pressure).

emerged for ε4 non-carriers (Table S3).

Cox proportional hazard models were used to evaluate the associations between serum biomarkers and incident MCI and dementia due
to possible/probable AD with covariate adjustment for age, sex, educa-

3.3

Serum biomarkers and clinical conversion

tion, site, APOE ε4 status, BMI, diabetes, and systolic blood pressure.
The GEE and cox proportional hazard models described above were

No serum biomarker values were associated with incident MCI

repeated with stratification by APOE ε4 carrier status (at least one ε4

(Table 4) or with further stratification by amnestic and non-amnestic

allele vs none). All statistical tests were two-sided. To adjust for mul-

MCI subtypes (Table S4). Across the six biomarkers examined, only

tiple comparisons, the criterion for significance was set at an false dis-

higher levels of baseline GFAP predicted incident dementia (Table 4,

covery rate (FDR)-corrected P-value of <.05. The adjusted P-values are

Figure 1). In nested models that examined incremental improvement

reported. Analyses were performed using SAS version 9.4.

of discriminating dementia risk with NFL and t-tau (biomarkers with
the second and third largest effect sizes) added to GFAP (largest effect
size), only GFAP was significant (hazard ratio [HR]: 1.440, 95% con-

3

RESULTS

fidence intervals [CI]: 1.010 to 2.054, adjusted P-value: 0.04), and Cstatistics were similar in all models (range: 0.8726 to 0.8739).

3.1

In stratified analyses by APOE ε4 carrier status, there were no

Participant characteristics

associations between serum biomarkers and incident MCI (Table
The study sample included 745 Mexican American participants, mean

S5). Among APOE ε4 non-carriers, serum GFAP levels were associ-

age ± SD (66 ± 9 years), of which 72% (n = 533) were female. At the

ated with incident dementia. There were no significant associations

baseline examination, which was conducted between 2007 and 2017,

between serum biomarkers and incident dementia among APOE ε4

approximately two-thirds of the sample was cognitively unimpaired,

carriers.

28% (n = 207) was diagnosed with MCI, and 8% (n = 59) was diagnosed
with dementia due to possible/probable AD (Table 1). The diagnostic
groups differed across most demographic and clinical factors. In addi-

4

DISCUSSION

tion, all raw blood biomarker levels except NFL differed significantly
across the diagnostic groups at baseline. Serum levels of GFAP were

The current study examined the efficacy of established and exploratory

higher among APOE ε4 carriers relative to non-carriers for the overall

ADRD blood biomarkers for predicting cognitive decline, clinical con-

sample, MCI, and dementia groups at baseline (Table S1). In addition,

version, and disease progression in a cohort of Mexican American older

serum NFL was higher among APOE ε4 carriers within the MCI group,

adults. Consistent with prior literature conducted primarily in non-

and UCHLI levels were lower among APOE ε4 carriers within the cog-

Hispanic White cohorts,27–30 we found that higher baseline t-tau, NFL,

nitively unimpaired group. Over the study interval, 29% (n = 138) of

and GFAP levels were associated with accelerated cognitive decline.

individuals who were cognitively unimpaired at baseline converted to

In addition, NFL and GFAP, along with less-established markers, YKL-

MCI and 7% (n = 50) of 686 participants without dementia at baseline

40 and sCD14, were associated with more rapid ADRD disease pro-

converted to dementia due to possible/probable AD.

gression as evaluated by the CDR Sum of Boxes. Stratified analyses
indicated stronger associations between blood biomarkers with cognitive decline and ADRD progression among APOE ε4 carriers relative to

3.2
Serum biomarkers, longitudinal cognitive
decline, and clinical progression

non-carriers. Of the six biomarkers examined, only higher baseline levels of GFAP were linked to increased risk of incident dementia due to
possible/probable AD. No additional biomarkers were significant when

Higher baseline serum NFL and GFAP levels were associated with

included in the model, suggesting that GFAP alone provided important

worsening global cognition over time (Table 2). In addition, higher base-

information relevant to incident dementia in our cohort of Mexican

line levels of GFAP, as well as t-tau, predicted accelerated decline on

American older adults.
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TA B L E 1

Demographic and clinical characteristics by baseline clinical diagnosis
Cognitively Unimpaired
N = 479

Mild Cognitive
Impairment N = 207

Dementia N = 59

P-value

Age, years

63 ± 7

71 ± 8

74 ± 8

<.001*

Female, no. (%)

354 (74%)

140 (68%)

39 (66%)

.15

11 ± 4

11 ± 4

11 ± 4

.57

31 ± 6

31 ± 6

29 ± 5

.50

Systolic

137 ± 20

138 ± 19

144 ± 19

.023*

Diastolic

78 ± 12

76 ± 10

75 ± 9

.002*

Diabetes, no. (%)

160 (33%)

77 (37%)

23 (39%)

.018*

Presence of APOE ε4 allele, no. (%)

99 (21%)

45 (22%)

24 (41%)

.009*

Raw serum t-tau, median (Quartile 1, Quartile
3), pg/mL

0.28 (0.13, 0.42)

0.29 (0.14, 0.44)

0.32 (0.19, 0.58)

<.001*

Raw serum NFL, median (Quartile 1, Quartile
3), pg/mL

15 (11, 21)

19 (15, 28)

26 (20, 36)

.088

Raw serum GFAP, median (Quartile 1,
Quartile 3), pg/mL

136 (102, 189)

179 (123, 261)

223 (160, 391)

<.001*

Raw serum UCHL1, median (Quartile 1,
Quartile 3), pg/mL

26 (22, 36)

29 (22, 39)

29 (24, 40)

<.001*

Raw serum YKL-40, median (Quartile 1,
Quartile 3), pg/mL

53506 (33701, 97333)

62291 (39586, 103909)

89030 52979,
47139079)

.013*

Raw serum sCD14, median (Quartile 1,
Quartile 3), pg/mL

1301 (1150, 1456

1318 (1172, 1554)

1295 (1178, 1536)

<.001*

Average follow-up length, years

4±2

4±2

3±2

0.29

MMSE

28 ± 2

27 ± 2

23 ± 4

<.001*

WMS LM I

35 ± 9

28 ± 9

22 ± 12

<.001*

WMS LM II

21 ± 7

16 ± 7

10 ± 8

<.001*

Animal Fluency

16 ± 4

14 ± 4

12 ± 4

<.001*

Trails A, time to completion (seconds)

45 ± 19

55 ± 29

79 ± 38

<.001*

Trails A, time to completion (seconds)

118 ± 59

171 ± 80

237 ± 81

<.001*

MMSE

0.01 ± 0.66

−0.18 ± 0.85

−0.86 ± 1.45

<.001*

WMS LM I

0.84 ± 2.27

0.54 ± 2.49

−0.27 ± 2.93

<.001*

WMS LM II

0.84 ± 1.75

0.66 ± 1.89

0.28 ± 2.05

.006*

Animal Fluency

0.01 ± 1.22

−0.23 ± 1.30

−0.63 ± 1.48

<.001*

Trails A, time to completion (seconds)

0.00 ± 5.57

0.93 ± 7.86

3.79 ± 12.75

<.001*

Trails A, time to completion (seconds)

2.86 ± 16.41

1.32 ± 18.59

5.74 ± 23.04

.034*

Education, years
Body mass index, m/kg

2

Blood pressure, mm Hg

Cognitive scores at baseline

Average annualized change in cognitive scores

Abbreviations: APOE = apolipoprotein E, MMSE = Mini Mental Status Examination, WMS LM = Weschler Memory Scale Logical Memory, Trails = Trail Making
Test, t-tau = total tau; NFL = neurofilament light, GFAP = glial fibrillary acidic protein, UCHL1 = ubiquitin carboxyl-terminal hydrolase L1, YKL-40 = chitinase3-like protein 1, sCD14 = soluble cluster of differentiation.
*P < 0.05. Group differences were assessed with Kruskal-Wallis tests for continuous variables and the chi-square test for categorical variables All values
represent mean ± standard deviation unless otherwise noted.

In alignment with prior research conducted primarily within nonHispanic White

populations,27,28,30

presumed to reflect neuronal injury.27 Blood t-tau levels have been

higher levels of t-tau, NFL, and

associated with multi-domain cognitive decline in numerous cohort

GFAP were associated with accelerated cognitive decline over time.

studies of neurodegenerative disease,27,32 as well as in association

Cerebral tau is considered a core biological marker of AD and closely

with other neurological conditions.33 In addition to t-tau, higher

correlates with cognitive

decline.31

Within the blood, t-tau levels are

baseline NFL was associated with faster global cognitive decline in
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Results of generalized estimating equation analyses displaying associations between serum biomarkers and longitudinal cognitive

t-tau

NFL

GFAP

UCHL1

YKL-40

sCD14

MMSE

β = −0.031,
SE = 0.040,
p = 0.65

β = −0.103,
SE = 0.041,
P = .034*

β = −0.141,
SE = 0.053,
P = .034*

β = −0.030,
SE = 0.033,
P = .65

β = −0.099,
SE = 0.034,
P = .79

β = −0.009,
SE = 0.036,
P = .79

WMS LM I

β = −0.344,
SE = 0.120,
P = .024*

β = −0.170,
SE = 0.122,
P = .22

β = −0.330,
SE = 0.129,
P = .032*

β = −0.011,
SE = 0.098,
P = .84

β = −0.154,
SE = 0.116,
P = .22

β = −0.244,
SE = 0.120,
P = .083

WMS LM II

β = −0.390,
SE = 0.088,
P < .001*

β = −0.113,
SE = 0.089,
P = .30

β = −0.260,
SE = 0.100,
P = .027*

β = −0.092,
SE = 0.080 P
= .30

β = −0.115,
SE = 0.088,
P = .30

β = −0.080,
SE = 0.089,
P = 0.37

Animal Fluency

β = −0.142,
SE = 0.056,
P = .05

β = −0.075,
SE = 0.057,
P = .28

β = −0.164,
SE = 0.069,
P = .05

β = −0.034,
SE = 0.067,
P = .73

β = −0.113,
SE = 0.053,
P = .07

β = −0.002,
SE = 0.007,
P = 0.98

Trails A

β = 0.408,
SE = 0.385,
P = .42

β = 0.656,
SE = .397,
P = .17

β = 0.955,
SE = .435,
P = .17

β = 0.768,
SE = .410,
P = .18

β = 0.334,
SE = 0.356,
P = .42

β = 0.183,
SE = 0.363,
P = .61

Trails B

β = 0.273,
SE = 0.882,
p = 0.91

β = 1.347,
SE = 0.841,
p = 0.40

β = 1.550,
SE = 1.030,
p = 0.40

β = 0.510,
SE = 0.891,
p = 0.85

β = 0.748,
SE = 0.814,
p = 0.72

β = −0.036,
SE = 0.833,
p = 0.97

Abbreviations: t-tau = total tau, NFL = neurofilament light, GFAP = glial fibrillary acidic protein, UCHL1 = ubiquitin carboxyl-terminal hydrolase L1, YKL-40
= chitinase-3-like protein 1, sCD14 = soluble cluster of differentiation 14, MMSE = Mini Mental Status Examination, WMS LM = Weschler Memory Scale
Logical Memory, Trails = Trail Making Test.
*FDR-corrected P < 0.05, Generalized estimating equation models with longitudinal cognitive data regressed on age, sex, ethnicity, APOE ε4 status, education,
site, clinical diagnostic group, body mass index, systolic blood pressure, diabetes, and serum biomarkers (modeled separately). β = coefficient associated with
time by standardized biomarker interaction.

F I G U R E 1 Serum glial fibrillary acidic protein (GFAP) and incident dementia: Kaplan-Meier curve derived from a cox proportional hazard
model evaluating the association between serum GFAP and incident dementia due to possible/probable Alzheimer’s disease with adjustment for
age, sex, education, site, apolipoprotein E (APOE) ε4 status, body mass index, diabetes, and systolic blood pressure
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TA B L E 3 Results of generalized estimating equation models
displaying associations between serum biomarkers and longitudinal
clinical progression

including multiple sclerosis and vascular dementia.36 Finally, higher
baseline levels of serum GFAP were associated with accelerated
cognitive decline across the domains of global cognition, learning,

CDR Sum of Boxes
N = 745

and memory in our cohort. GFAP is an intermediate filament found in

β = 0.033,
SE = 0.025, P = .18

marker of astroglial injury and has higher expression in the brains of

β = 0.099,
SE = 0.026, P<.001*

have been found to predict incident cognitive decline even among indi-

GFAP

β = 0.125,
SE = 0.036, P = .001*

occur early in the disease process. Similar to t-tau and NFL, GFAP is not

UCHL1

β = 0.038,
SE = 0.024, P = .14

the context of multiple neurological conditions and acute CNS injury.40

YKL-40

β = 0.044,
SE = 0.016, P = .010*

between biomarkers and ADRD clinical progression based on the CDR

sCD14

β = 0.036,
SE = 0.017, P = .048*

cognition and functional status.23 In alignment with our cognitive find-

t-tau
NFL

Abbreviations: t-tau = total tau, NFL = neurofilament light, GFAP = glial
fibrillary acidic protein, UCHL1 = ubiquitin carboxyl-terminal hydrolase L1,
YKL-40 = chitinase-3-like protein 1, sCD14 = soluble cluster of differentiation 14.
*FDR-corrected P < 0.05, Generalized estimating equation models with longitudinal clinical progression data (Clinical Dementia Rating Scale Sum of
Boxes) regressed on age, sex, ethnicity, APOE ε4 status, education, site, clinical diagnostic group, body mass index, systolic blood pressure, diabetes,
and serum biomarkers (modeled separately). β = coefficient associated with
time by standardized biomarker interaction.

the cytoskeletons of mature astrocytes.37 It is considered a putative
individuals with AD relative to controls.38 In the blood, GFAP levels
viduals without cognitive impairment,30,39 suggesting that elevations
specific to neurodegenerative disease and has been found to change in
In addition to cognitive decline, we evaluated the associations
Sum of Boxes, a gold standard tool for evaluating interval change in
ings, higher baseline levels of serum GFAP and NFL were associated
with worsening disease severity. Although serum t-tau was associated
with cognitive decline in our sample, it surprisingly did not predict
changes in disease progression. A prior study by Rajan et al. reported
that plasma GFAP and NFL predicted incident AD over a period of 4 to 8
years prior to clinical diagnosis, whereas t-tau was only associated with
AD 8 to 16 years prior to diagnosis.29 Therefore, the 4-year longitudinal follow-up period in our study may have been too short to appreciate
associations between t-tau and clinical progression.
In our study, higher baseline levels of sCD14 and YKL-40, which
are considered putative markers of glial injury and neuroinflammation,

our Mexican American cohort. NFL is an intermediate filament protein

were also associated with advancing disease progression over time.

found in myelinated axons.34 Within blood, NFL levels are considered

sCD14 is a glycoprotein found in monocytes and neutrophils with inte-

a marker of axonal/neuronal damage.35 NFL levels in blood closely

gral role in governing innate immunity and inflammatory cascades.41

correlate with CSF levels,28 suggesting that blood may serve as a viable

YKL-40 is a glycoprotein expressed in numerous bodily tissues, includ-

proxy for the extent of axonal/neuronal damage in the CNS. Individual

ing within astrocytes and microglia in the CNS.42 Consistent with our

and meta-analytic studies have reported that NFL predicts cognitive

findings, previous studies have reported associations between blood

decline in AD,28,29,32 as well as in broader neurological conditions

sCD14 and YKL-40 levels and ADRD.43,44 In our sample, sCD14 and

TA B L E 4

Results of cox proportional hazard models displaying for incident mild cognitive impairment and dementia
MCICases = 138/479

DementiaCases = 50/686

t-tau

HR = 1.037,
95% CI = 0.867-1.241, P = .69

HR = 1.399,
95% CI = 1.032—1.896, P = .07

NFL

HR = 0.932,
95% CI = 0.770-1.129; P = .57

HR = 1.360,
95% CI = 1.024—1.805, P = .07

GFAP

HR = 0.901,
95% CI = 0.724-1.120, P = .57

HR = 1.611, 95% CI = 1.204—2.155, P = 0.008*

UCHL1

HR = 1.065,
95% CI = 0.915-1.238, P = .57

HR = 1.106,
95% CI = 0.826—1.432, P = .75

YKL-40

HR = 1.075,
95% CI = 0.903-1.279, P = .57

HR = 0.980,
95% CI = 0.708—1.356, P = .90

sCD14

HR = 0.936,
95% CI = 0.784-1.116, P = .57

HR = 0.968, 95% CI = 0.714—1.313, P = .90

Abbreviations: t-tau = total tau, NFL = neurofilament light, GFAP = glial fibrillary acidic protein, UCHL1 = ubiquitin carboxyl-terminal hydrolase L1, YKL-40 =
chitinase-3-like protein 1, sCD14 = soluble cluster of differentiation 14.
*FDR-corrected P < 0.05, Cox proportional hazard models for incident mild cognitive impairment and dementia with adjustment for age, sex, ethnicity, APOE
ε4 status, education, site, clinical diagnostic group, body mass index, systolic blood pressure, diabetes, and serum biomarkers (modeled separately).
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YKL-40 were not significantly associated with cognitive decline, which

between APOE ε4 carrier status and ADRD biomarker levels within this

may be partially attributable to the enhanced utility of considering

ethnic group.

both cognitive and functional outcomes when using the CDR. This

Our study has several strengths including a sizable Mexican Ameri-

is particularly relevant for diverse ethnoracial groups given inherent

can cohort with well-characterized clinical and cognitive profiles, lon-

biases in cognitive tests due to variances in educational quality, linguis-

gitudinal monitoring, and inclusion of multiple established and more

tic background, and culture.7,45

novel blood biomarkers. However, the findings of the study must also

In our sample, none of the blood biomarkers were associated with

be considered in the context of the limitations. It is important to

incident MCI. Individuals with MCI have variable long-term outcomes,

note that our study lacks available brain MRI, CSF, and PET imag-

spanning from improvement or stability to progression to dementia.46

ing outcomes, preventing further confirmation of suspected diagnos-

The heterogeneity of the underlying cause of the diagnosis makes the

tic etiology.31 That being said, our study employs routine clinical and

identification of accurate biomarkers challenging. Furthermore, our

cognitive assessments for dementia workup, making the findings rel-

cohort lacks broader biomarker data, including brain magnetic reso-

evant to the clinical setting, particularly in underserved communities

nance imaging (MRI), CSF, and positron emission tomography (PET)

with more limited access to neuroimaging. Another potential limita-

imaging outcomes, which can be used to further improve discrimina-

tion is that our study included biospecimens that were collected across

tion of underlying disease etiology.31

multiple institutions over the course of many years, which may lead

Across the six biomarkers examined, only baseline GFAP levels were

to variability in biomarker values.4 In addition, the annualized rate of

associated with increased risk of incident dementia in our Mexican

cognitive decline was small and only a small percentage of individuals

American cohort. Although blood GFAP levels have been less exten-

converted to dementia, which may have limited our power for detect-

sively examined in ADRD research relative to t-tau and NFL, grow-

ing significant associations. Furthermore, the participants enrolled in

ing literature indicates its strong predictive utility.29,30,39 In addition,

TARCC were recruited from academic institutions for the purpose

previous studies have reported that core AD biomarkers such as tau

of developing a consortium of AD Centers, which may pose limits

and amyloid beta may have poorer discriminability for ADRD in some

to generalizability. Finally, our study was solely comprised of Mexi-

diverse ethnoracial

groups.11,13

Within a cohort of Mexican Ameri-

can Americans and aimed to advance the identification of biomarkers

can adults, O’Bryant et al. reported that plasma Aβ42 and t-tau were

that are most predictive of incident dementia risk within this ethnic

less important for classifying dementia relative to their utility in non-

group. Future studies with well-matched samples, harmonized proto-

Hispanic Whites, whereas inflammatory and metabolic markers had

cols, and adequate representation of multiple diverse groups are criti-

stronger predictive value.13 These results, coupled with our findings,

cally needed to evaluate ethnoracial differences in biomarker values,7

highlight the potential value of examining biomarkers beyond the tra-

as well as to establish the multidimensional determinants of health that

ditional Aβ and tau pathways, particularly among Mexican American

may contribute to observed variances.

cohorts.

In summary, our study examined both established and more novel

As an exploratory aim, we examined associations between blood

ADRD blood biomarkers reflecting diverse pathophysiological pro-

biomarkers with cognitive decline and clinical progression with stratifi-

cesses in a cohort of Mexican American older adults. We found that

cation by APOE ε4 status. For cognitive decline and ADRD progression,

higher baseline levels of t-tau, NFL, and GFAP were associated with

significant associations were typically only observed among APOE ε4

accelerated cognitive decline. In addition, NFL and GFAP, as well as

carriers. For incident dementia, the association with GFAP was only sig-

sCD14 and YKL-40, were associated with disease progression over

nificant among APOE ε4 non-carriers, which may be attributable to the

time, highlighting the important role of neuroinflammatory processes.

smaller sample size and more limited power within the APOE ε4 carrier

Finally, we found that only baseline levels of serum GFAP were associ-

group. Although some previous studies conducted in predominately

ated with increased risk of dementia in our sample. With further vali-

non-Hispanic White populations have not found APOE-related differ-

dation, GFAP,potentially in combination with blood biomarkers beyond

ences in biomarker

levels,47,48

there is some evidence that markers of

those included in our study, may optimize dementia risk prediction in

astrogliosis, such as CSF YKL-40 levels, may be higher among APOE ε4

Mexican American older adults, providing avenues for earlier diagno-

carriers within the early disease stage.49 The results of more robust

sis, more accurate prognosis, and improved risk stratification for clini-

associations between blood biomarkers and interval cognitive change

cal trials.

among APOE ε4 carriers within our cohort is somewhat surprising, as
prior studies have reported weaker associations between the APOE
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